Navigation Links
MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results
Date:8/3/2009

MOUNTAIN VIEW, Calif., Aug. 3 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the second quarter ended June 30, 2009.

The net loss for the quarter ended June 30, 2009 was $5.0 million, compared to $16.5 million during the same period in 2008. The net loss for the first six months of 2009 was $14.9 million, compared to $30.8 million for the first six months of 2008. As of June 30, 2009, MAP Pharmaceuticals had cash, cash equivalents, short-term investments and accounts receivables of $59.9 million.

"We are very pleased that in the first Phase 3 trial for our LEVADEX(TM) migraine therapy, all four primary endpoints were met with statistical significance," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "With these positive results in hand and our recent decision to suspend development of Unit Dose Budesonide (UDB), we are now focusing our efforts on the development of LEVADEX. We believe that LEVADEX has a differentiated profile, with the potential to provide rapid and sustained relief of migraine symptoms, and could offer benefit to many of the approximately 30 million migraine sufferers in the U.S., including many who are not helped by currently available migraine therapies. We look forward to presenting the data from our successful Phase 3 trial of LEVADEX at the 14th Congress of the International Headache Society in September."

Second Quarter and Six Month Financial Results

Revenues for the quarter and six months ended June 30, 2009 were $8.6 million and $16.1 million, respectively, compared to $0 for the same periods in 2008. The collaboration revenue to date in 2009 was due to the amortization of a $40.0 million upfront payment received in February
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... heart disease among women and men and among blacks ... ethnicity matter when it comes to health research. The ... a Foundation for Understanding, a new report from the ... researchers identify and address the needs of LGBT populations. ...
... certain types of cancer has shown promising results in ... from an open-label Phase II trial. While the drug,s ... the gold standard for testing a drug, researchers are ... against the chronic connective tissue disease for which a ...
... studies that show a drop in the black percentage ... statistical aberrations, according to a group of criminologists. The ... jump in black violent crime during the late 1980s ... Uniform Crime Reports and the National Crime Victimization Survey ...
... -- Teenagers who begin smoking at an early age are ... they,re 17, researchers report. Their analysis of data from ... that by the time they were 17, about 15 percent ... or other illicit substances at least once. Predictors of ...
... at the University of California, San Diego School of Medicine ... in public health and suggest that surgery should become an ... recent study led by David C. Chang, PhD, MPH, MBA, ... UCSD School of Medicine, points out that surgery in the ...
... Most women face only a small risk of breast cancer ... study from the University of Michigan Comprehensive Cancer Center finds ... a great deal of worry about recurrence. "Some worry ... worries can be so strong that they impact their treatment ...
Cached Medicine News:Health News:Cancer drug shows promise for treating scleroderma 2Health News:Cancer drug shows promise for treating scleroderma 3Health News:Demographics cloud optimism on black violent crime decrease 2Health News:Surgeon availability tied to survival rate in vehicle crashes 2Health News:Some women worry too much about breast cancer returning, U-M study finds 2
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... less invasive, miniaturized circulatory support technologies that are ... announced that it expects revenues for the fourth ... bringing expected full-year 2013 revenues to approximately $208 ... 87% for 2013 above 2012 reflects the first ...
(Date:1/14/2014)... HILLS, Calif. , Jan. 14, 2014 The ... offers Los Angeles a premier and ... laser and a $99 treatment special. Dr. Brandeis, focus is ... technology and offering expert medical advice to all patients. ... dramatic increase in the presence of tattoo regret and patients ...
(Date:1/14/2014)... LEESBURG, Va. , Jan. 14, 2014 Animal Emergency ... Road in Leesburg, Virginia is the first ... animal hyperbaric oxygen chamber. Dr. Susan M. ... 30 years. Dr. Barnes and husband, Dr. Cole Taylor , ... increased exertion and need for oxygen when air is thin," states ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Wide 1 mm x 3 mm smooth platform. Serrated handle with polished finish. Most popular size or model....
Oval solid 15 mm wide lower plate. Open upper plate with inside dimensions 11 mm x 8 mm. Serrated handle with locking thumb screw and polished finish....
Fine 2 mm wide platform. Cross action serrated handle with metal tip guard. Polished finish....
Medicine Products: